Conventional chemotherapy

Either hydroxyurea or busulfan as single agents can provide hematological control in the majority of patients (>75%) with chronic-phase CML. These hematological 'remissions' are characterized by persistence of Philadelphia chromosome-positive cells in the marrow, with inevitable progression to the blastic phase. Suppression of Philadelphia chromosome posi-tivity has been observed occasionally during treatment with busulfan or hydroxyurea, usually in the setting of therapy-induced myelosuppression, and is transient. A prospective, randomized trial comparing these two agents in chronic-phase CML found a significantly prolonged median duration of the chronic phase in hydroxyurea-treated patients: 47 months versus 37 months with busulfan (P = 0.04). Overall survival was also superior in hydroxyurea-treated patients, with a median survival of 58 months versus 45 months (P = 0.008) in the busulfan group. Additionally, hydroxyurea has a lower toxicity profile than busulfan.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment